Unlike bevacizumab's long 20-day half-life and associated bleeding risks that excluded squamous cell carcinoma patients, new bispecifics have a ~6-day half-life. This results in a similar but less severe toxicity profile, broadening their clinical application to a wider patient population.
Beyond simply blocking the PD-1/PD-L1 pathway, these bispecifics may form a macromolecular structure with VEGF and PD-L1 in the tumor microenvironment. This structure can cause the cancer cell to internalize the PD-L1 protein, effectively removing it as a target and creating a dual blockade.
With multiple PD-L1/VEGF bispecifics showing similar high efficacy, the ultimate market leader will likely be determined by strategic clinical trial design—including patient selection, endpoint ambition, and generation of robust global data—rather than minor molecular differences between the compounds.